Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma
CONCLUSIONS: Based on the very low-certainty evidence found in four trials in people with curative-intent resection for cholangiocarcinoma, we are very uncertain of the effects of postoperative adjuvant chemotherapy (mitomycin-C and 5-FU; gemcitabine; gemcitabine plus oxaliplatin; or capecitabine) versus no postoperative adjuvant chemotherapy on mortality. The effects of postoperative adjuvant chemotherapy compared with no postoperative adjuvant chemotherapy on serious adverse events are also very uncertain, but the result of the single trial showed 20% higher occurrences of haematologic adverse events. We assessed the certainty of the evidence as very low due to overall high risk of bias, and imprecision. Due to insufficient power of the only identified trial, the best postoperative adjuvant chemotherapy regimen in people with only cholangiocarcinoma could not be established. We also lack randomised clinical trials with outcome data on adjuvant S-1 chemotherapy versus adjuvant gemcitabine-based chemotherapy in people with cholangiocarcinoma alone. There is a need for further randomised clinical trials designed to be at low risk of bias and with adequate sample size exploring the best adjuvant chemotherapy treatment after surgery in people with cholangiocarcinoma.PMID:34515993 | DOI:10.1002/14651858.CD012814.pub2
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Vor Luvira Egapong Satitkarnmanee Ake Pugkhem Chumnan Kietpeerakool Pisake Lumbiganon Porjai Pattanittum Source Type: research
More News: Bile | Bile Duct Cancer | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Cholangiocarcinoma | Clinical Trials | Conferences | Databases & Libraries | Eloxatin | France Health | Gallbladder Cancer | General Medicine | Japan Health | Oral Cancer | Science | UK Health | Xeloda